The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Revolutionary technology will further boost OneSource’s scientific services offerings
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
Decision on EU marketing authorisation for this population expected by September 2024
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Multidisciplinary central team deployed to assist Gujarat with epidemiological, environmental, and laboratory investigations of AES cases
Subscribe To Our Newsletter & Stay Updated